SLU7 and myelodysplastic syndrome: Myelodysplastic syndromes (MDS) are hematopoietic stem cell neoplasms with heterogeneous outcome and limited therapeutic options in which somatic mutation in splicing factor (SF) genes is a cardinal feature1.